Linked Life Data

1828765

Source:http://linkedlifedata.com/resource/pubmed/id/1828765

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1991-7-25
pubmed:abstractText
Procaterol is a new, potent, long-acting beta-2-adrenergic bronchodilator. The magnitude and duration of the immediate bronchodilatation produced by inhaled procaterol aerosol have been compared with those produced by inhaled salbutamol aerosol in 20 asthmatic patients. Patients inhaled two puffs of procaterol (20 micrograms) or two puffs of salbutamol (200 micrograms) and PEF, FVC and FEV1 were measured after 5, 15, 30, 60, 120 and 180 min. The changes in mean PEF, FEV1 and FVC values were greater after procaterol than salbutamol, but the difference in bronchodilatation was not significant. The response to rimiterol after 180 min was greater in the salbutamol group. The increases in heart rate and systolic blood pressure were slightly higher after procaterol. Eleven patients reported adverse effects; 5 after procaterol, 3 after salbutamol, and 3 after both drugs. Thus, procaterol was a potent bronchodilator when inhaled as a single dose of 20 micrograms, but it did not appear to be an ultra long-acting preparation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0031-6970
pubmed:author
pubmed:issnType
Print
pubmed:volume
40
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
417-8
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Inhaled procaterol versus salbutamol in bronchial asthma.
pubmed:affiliation
Department of Diseases of Chest, Turku University Central Hospital, Finland.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial